Back to Agenda
Session 5: Education
Session Chair(s)
Hillel P Cohen, PHD
Biosimilars Expert, Retired, United States
Because the US approval pathway for biosimilars and interchangeable biologics is relatively new, it is important to ensure appropriate information about these products is available for those making critical decisions about prescribing or their own treatment options. In this session, an assessment of the current understanding of US health care professionals and the public of the concepts of biosimilars and interchangeable biologics will provide insights into the areas for which education is needed. Ongoing and future programs designed by a patient advocacy group and a professional society for their memberships will illustrate varied approaches to accomplishing goals for biosimilar education.
Speaker(s)
Dorothy A McCabe, PHD
Executive Director, Boehringer-Ingelheim, United States
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Samantha Roberts, PHD
Senior Director, Regulatory Intelligence, AstraZeneca, United States
Biosimilars Education - Patient Needs and Perspectives
Mary Jo Carden, JD
, Carden Associates, United States
AMCP Initiatives on Biosimilars Education
Panel Discussion
, All Session Speakers, United States
Leah Christl, PHD
Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy, Amgen, United States
Panelist
Have an account?